Despite this, PMI values were significantly higher in the insulin group than the oral antidiabetic group (Table 2 and Table 3 and Figure 2 and Figure 3), indicating that insulin therapy reduces sarcopenia risk regardless of diabetes duration. This evidence concerns the gene INS and diabetes mellitus.